Serum Anti-Mullerian Hormone (AMH) Levels in Overweight and Obese Adolescent Girls With Polycystic Ovaries
Condition: Polycystic Ovary Syndrome
MeSH terms: Polycystic Ovary Syndrome
Study type: Observational

Summary: 
      In this study the investigators aimed to investigate whether there is a relation between body
      weight and serum anti mullerian hormone levels in adults with polycystic ovary syndrome. For
      this purpose the investigators designed a prospective study including three groups. The group
      I is defined as adults with polycystic ovary syndrome and body mass index is greater than 25.
      The group II is defined as adults with polycystic ovary syndrome and body mass index is less
      than 25. The group III is defined as adults with non-polycystic ovary syndrome and body mass
      index is less than 25. The all three groups are compared considering their serum AMH
      levels,lipid profiles, sex steroids and glycemic analyses.
    

Detailed description: 
      In this study the investigators aimed to investigate whether there is a relation between body
      weight and serum anti mullerian hormone levels in adults with polycystic ovary syndrome. For
      this purpose the investigators designed a prospective study including three groups. The
      diagnosis of polycystic ovary syndrome was made in the presence of ;oligo- and/or
      anovulation,clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries.
      Clinical hyperandrogenism was defined by the presence of hirsutism , acne, or the presence of
      androgenic alopecia , biochemical hyperandrogenemia was defined as a serum level of total
      testosterone higher than 2.60 nmol/L, body mass index (BMI) was calculated as weight in
      kilograms divided by the square of height in meters. The patients were classified as obese
      with BMI ≥ 25 kg/m2 , adolescent patients were diagnosed 2 years after menarche in order to
      avoid the misdiagnosis of transitory functional hyperandrogenism and menstrual disorders
      during puberty. The all three groups are compared considering their serum AMH levels,lipid
      profiles, sex steroids and glycemic analyses.
    

Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        The diagnosis of Polycystic ovary syndrome was made in the presence of ;oligo- and/or
        anovulation,clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries.
        Clinical hyperandrogenism was defined by the presence of hirsutism, acne, or the presence
        of androgenic alopecia , biochemical hyperandrogenemia was defined as a serum level of
        total testosterone higher than 2.60 nmol/L, body mass index (BMI) was calculated as weight
        in kilograms divided by the square of height in meters. The patients were classified as
        obese with BMI ≥ 25 kg/m2 , adolescent patients were diagnosed 2 years after menarche in
        order to avoid the misdiagnosis of transitory functional hyperandrogenism and menstrual
        disorders during puberty.
      
Keywords: polycystic ovary syndrome; Anti-Mullerian Hormone; obesity